Lake Street analyst Thomas Flaten lowered the firm’s price target on BioLife Solutions to $15 from $25 and keeps a Buy rating on the shares after the company reported Q3 results and confirmed 2023 revenues would be at the low end of guidance. The completion of the freezer business divestiture is targeted for early 2024 and the firm is updating its 2024 outlook to exclude freezers while adjusting its price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BLFS:
- BioLife Solutions still sees 2023 revenue at low end of $144M-$158M
- BioLife Solutions reports Q3 EPS (67c), consensus (38c)
- BioLife Solutions Reports Third Quarter 2023 Financial Results
- BLFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insider Trading: BioLife Solutions Stock (NASDAQ:BLFS) Gains on Huge Insider Buy
